top of page
News, Events and Updates
Search
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
Sep 9
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Sep 2
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
Aug 26
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
Aug 20
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Aug 12
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Aug 5
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Jul 31
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
May 14
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
May 6
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
May 1
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
Apr 30
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
Apr 23
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
Apr 21
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Apr 5
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
Feb 24
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Feb 12
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Feb 5
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Jan 27
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
